Financial Performance - The net loss for Q3 2024 was approximately 2.6 million in Q3 2023, indicating a reduction in losses[10]. - Selling, general and administrative expenses decreased to approximately 1.1 million in Q3 2023[10]. - Research and development expenses for Q3 2024 were approximately 1.9 million in Q3 2023, reflecting the completion of enrollment in the CardiAMP Cell Therapy Heart Failure Trial[9]. Funding and Assets - The company closed a 6.267 million as of September 30, 2024, compared to $2.987 million as of December 31, 2023[19]. Clinical Trials and Regulatory Updates - The FDA accepted plans for completing patient follow-up in the CardiAMP Heart Failure Trial, with final data transfer expected in Q1 2025[2]. - A submission to Japan's PMDA has been completed, with a consultation scheduled for late November 2024[3]. - The FDA approved a protocol amendment for the CardiAMP Heart Failure II Trial, increasing patient eligibility[4]. - The last patient in the low-dose cohort of the CardiALLO Cell Therapy is expected to be enrolled in Q4 2024[5]. - The company anticipates top line data release for the CardiAMP Heart Failure Trial in Q1 2025[11].
BioCardia(BCDA) - 2024 Q3 - Quarterly Results